Antibody Cross-Reactivity in Virus Infection

Dear Colleagues,

This Special Issue on “Antibody Cross-Reactivity in Virus Infection” will showcase recent research on various topics surrounding antibody cross-reactivity in natural infection, diagnostics, vaccines, and therapeutics. Antibodies developed after a viral infection can have protective or pathological effects. These antibodies can either be specific to the virus that caused the disease or react with closely related viruses or hosts. The function of these antibodies may depend on their Fc effector functions. This Special Issue invites articles from basic and translational research that may include areas such as the dynamics of cross-reactive antibody responses following natural infection or vaccination, defining cross-reactive epitopes, Fc effector properties of cross-reactive antibodies, strategies for eliciting cross-protection antibodies with or without Fc effector functions, and issues of antibody cross-reactivity in serodiagnosis and seroepidemiological studies. This Special Issue is also looking for papers that address antibody-dependent disease enhancement, autoantibody-mediated diseases, the development of broadly neutralizing therapeutic antibodies, approaches for eliminating antibody cross-reactivity in serodiagnostics, the prediction of cross-reactive epitopes, and the design of immunogens to preserve or eliminate the induction of vaccine-induced cross-reactive antibodies. The development of methods and technological advancements such as cellular and plate- or bead-based assays for characterizing cross-reactive antibodies is also encouraged. The viruses may include those that cause respiratory or gastrointestinal infections, arboviruses such as dengue, Zika, and chikungunya, and other zoonotic viruses and viruses from veterinary virology. We welcome reviews, original research, and communications for this Special Issue.

Dr. Lakshmanane Premkumar
Prof. Dr. Christian Jassoy
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Viruses is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

• viral infection
• neutralizing antibodies
• non-neutralizing antibodies
• cross-reactive epitopes
• Fc effector functions
• antibody-dependent cellular phagocytosis
• antibody-dependent disease enhancement
• broadly protective antibodies
• antigen design
• vaccine design